General Information
Drug ID
Drug Name
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel
Drug Type
Small molecular drug
Indication Breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Therapeutic Class
Anticancer Agents
<iframe style="width: 300px; height: 300px;" frameborder="0" src=""></iframe>
Canonical SMILES
CAS Number
CAS 33069-62-4
Pharmaceutical Properties Molecular Weight 853.918 Topological Polar Surface Area 221
Heavy Atom Count 62 Rotatable Bond Count 14
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 14
PubChem CID
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MDR3 Transporter Info Multidrug resistance protein 3 Substrate [3]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [4]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [5]
MRP3 Transporter Info Multidrug resistance-associated protein 3 Substrate [6]
MRP7 Transporter Info Multidrug resistance-associated protein 7 Substrate [7]
OAT2 Transporter Info Organic anion transporter 2 Substrate [8]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [9]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [10]
P-GP Transporter Info P-glycoprotein 1 Substrate [11]
TAPL Transporter Info TAP-like protein Substrate [12]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OAT2 Transporter Info Km = 0.1428 microM Oocytes-OAT2 [8]
OATP1B3 Transporter Info Km = 6.79 microM Oocytes-OATP1B3 [10]
P-GP Transporter Info Km = 0.014 microM Breast carcinoma cell line (MCF7)-MDR1 [11]
P-GP Transporter Info Km = 16.5 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [13]
P-GP Transporter Info Km = 65 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [14]
P-GP Transporter Info Km = 0.7 microM Spodoptera frugiperda (Sf9) cells-MDR1 [15]
P-GP Transporter Info Km = 1.4 microM Spodoptera frugiperda (Sf9) cells-MDR1 [16]
1 Paclitaxel was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
3 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
5 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
6 Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
7 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
8 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
9 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
10 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
11 Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
12 Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
13 Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998 Apr;26(4):343-6.
14 Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
15 Synthesis and evaluation of 3D templates based on a taxane skeleton to circumvent P-glycoprotein-associated multidrug resistance of cancer. Bioorg Med Chem Lett. 2005 May 16;15(10):2601-5.
16 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.